- In November 2022, A clinical trial of Tree MATA MPL or Tree MATA immunotherapy for allergic rhinitis and type I hypersensitivity was terminated due to insufficient subject enrollment. Sponsored by Allergy Therapeutics, known for subcutaneous and sublingual immunotherapy, the trial aimed to explore new treatments but faced challenges in recruiting participants
- In November 2020, Dr. Reddy's Laboratories announced plans to acquire several brands from Glenmark Pharmaceuticals, including Momat Rino and Glenspray variants, pending final approvals and procedural steps across Russia, Kazakhstan, Uzbekistan, and Ukraine
- In May 2021, Glenmark Pharmaceuticals launched Ryaltris nasal spray in India, expanding treatment options for moderate to severe allergic rhinitis. This initiative aimed to enhance growth prospects in the allergic rhinitis sector, providing a new therapeutic option for patients in the region
- In April 2021, ALK received FDA approval for its short ragweed pollen allergen extract, designed for patients aged 5 to 65 with short ragweed pollen-induced allergic rhinitis. This milestone marked a significant advancement in expanding treatment options for seasonal allergies in the United States
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Allergic and Non-Allergic), Treatment (Antihistamines, Intranasal Corticosteroids, Immunotherapies, Decongestants, and Others), Route of Administration (Oral, Nasal, and Others), End-Users (ENT Centers, Clinics, Hospitals, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) – Industry Trends and Forecast to 2031
.
The Global Acute Rhinitis Market size was valued at USD 995.76 USD Million in 2023.
The Global Acute Rhinitis Market is projected to grow at a CAGR of 5.76% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
